Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
Elagolix save search
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
Published: 2022-06-17 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.25 -0.27% 9.9M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 3.13%
H: 8.66%
C: 6.63%
sciences women lancet therapy publication phase 3
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
Published: 2022-04-29 (Crawled : 00:20) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
orgovyx treatment approval cancer prostate cancer
Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
Published: 2022-02-25 (Crawled : 14:00) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 1.23%
H: 0.0%
C: 0.0%
orgovyx treatment prostate cancer state positive cancer chmp
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
Published: 2021-10-19 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.25 -0.27% 9.9M
|
Health Technology
|
| O: 0.68%
H: 1.44%
C: 1.18%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 0.3%
H: 3.0%
C: -0.15%
uterine fibroids therapy
Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
Published: 2021-05-21 (Crawled : 13:00) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 1.71%
H: 4.69%
C: 1.59%
treatment positive women chmp
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
Published: 2021-04-12 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.25 -0.27% 9.9M
|
Health Technology
|
| O: -0.33%
H: 1.52%
C: 1.34%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.39%
H: 0.5%
C: -4.98%
phase 3 contraceptive
Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
Published: 2021-03-29 (Crawled : 11:00) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.09%
H: 0.21%
C: -2.6%
treatment prostate cancer cancer authorized application
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Published: 2021-03-24 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.25 -0.27% 9.9M
|
Health Technology
|
| O: 0.34%
H: 1.27%
C: 0.37%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 0.3%
H: 1.17%
C: -7.12%
positive therapy women phase 3
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Published: 2021-02-17 (Crawled : 22:04) - globenewswire.com
PFE | News 4 | $26.25 -0.27% 9.9M
|
Health Technology
|
| O: -0.32%
H: 0.28%
C: -0.63%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.89%
H: 3.7%
C: 3.11%
therapy women phase 3
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Published: 2021-01-26 (Crawled : 12:00) - globenewswire.com
PFE | News 4 | $26.25 -0.27% 9.9M
|
Health Technology
|
| O: -0.03%
H: 0.89%
C: 0.11%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 4.44%
H: 9.52%
C: 4.67%
positive therapy phase 3
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Published: 2020-12-28 (Crawled : 12:00) - globenewswire.com
PFE | News 4 | $26.25 -0.27% 9.9M
|
Health Technology
|
| O: 0.24%
H: 0.59%
C: -1.45%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 32.66%
H: 2.39%
C: -9.18%
collaboration commercialization announces collaboration health
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
Published: 2020-12-18 (Crawled : 22:01) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
prostate cancer approval fda fda approval cancer hormone
Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
Published: 2020-05-29 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
cancer positive phase 3 prostate cancer cardio cardiovascular
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Published: 2020-06-01 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
fda drug new drug treatment application
Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
Published: 2020-06-22 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
cancer fda drug prostate cancer fda acceptance new drug
Myovant Sciences to Host Webcast and Conference Call at 8:30 am Eastern Time Tuesday, June 23 to Discuss Results from Phase 3 SPIRIT 1 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Published: 2020-06-22 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
therapy results phase 3
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Published: 2020-06-23 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
therapy positive results positive results phase 3
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study
Published: 2020-07-06 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
therapy phase 3
Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
Published: 2020-08-17 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
fda drug fda acceptance new drug application
Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
Published: 2020-09-29 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
cancer results phase 3 prostate cancer
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $28.605 31.7% 9.9M
|
Finance
RBBN 4 | $3.305 28.6% 1.9M
|
Electronic Technology
RCAT | $1.53 27.5% 2.9M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.